Category Archives: Immunology

Update to Previously Announced SARS-CoV-2 Test Development Initiative With Albany Medical College for the Presence of SARS-CoV-2 Virus – GlobeNewswire

September 8, 2020 medical

CALGARY, Alberta, Sept. 08, 2020 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (FluroTech or the Company) is pleased to provide an update to its press releases dated April 16 and 20, 2020 in respect of FluroTest LLC (FluroTest), formed through a strategic agreement with the Company, Alberta BioPhotonics Inc. (ABP) and Albany Medical College (AMC) today confirmed successful function of its novel and proprietary low-cost, real-time, point-of-care saliva-based immunoassay for detecting active SARS-CoV-2 infections.

The science behind the FluroTest virus direct detection method is based on a vertical flow immunoassay configuration which utilizes fluorescence spectroscopy to quantitatively determine SARS-CoV-2 viral load in salivary samples. Prototype testing was conducted at Albany Medical Colleges immunology laboratories in Albany, New York supported by FluroTechs Calgary Laboratory.

FluroTest intends to immediately begin the process of seeking Emergency Use Authorization (EUA) status from the U.S. Food and Drug Administration (FDA) in order to commercialize its pandemic platform solution. FluroTest will better understand the costs, time requirements, and next steps for commercialization once the FDA provides further guidance.

The FluroTest solution is a saliva-based, point of collection diagnostic immunoassay designed for accurate, digitally verifiable results, delivered with high throughput capacity, which are transmitted to a secure, managed, cloud environment compliant with thestandards for privacy of individually identifiable health information as promulgated in theU.S. Health Insurance Portability and AccountabilityAct of 1996 (HIPAA).

By combining and leveraging the disciplines of robotics automation, biochemistry (antibody labeling and binding), fluorescence detection and cloud computing, FluroTest believes that it is creating the first pandemic defense platform of its kind. FluroTest anticipates a single platform installation could serve over 3,000 test takers per hour with digitally verifiable results transmitted to a secure, managed, HIPAA compliant cloud environment and immediately available to the test takers mobile device within 5 minutes. The platform is intended to make it possible to test up to 100% of a specific community population every 4 to 7 days at a low cost to the test taker and high value to the communities served by the platform.

FluroTest believes that its pandemic defense platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to: colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.

FluroTest believes its technology can also be adapted to allow for the detection of specific anti-SARS-CoV-2 human antibodies, potentially confirming the development of immunity.

Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the early stages of research and development and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus. In addition, FluroTest requires additional capital in the near-term to further the development and deployment of its testing device and will be seeking equity investors and is exploring strategic partnerships in connection with the same.

The Team

FluroTests technology development efforts require unique expertise in spectroscopy and fluorescence as well as immunology and virology. This initiative is a collaborative effort between U.S. and Canadian scientists with deep experience in their respective fields.

For immunology and virology expertise, FluroTest has partnered with Albany Medical Colleges immunology and microbial disease department. AMC is located in the State of New York. The Departments research team is led by Dennis Metzger, Ph.D., professor and chair of the department, along with assistant professor Kouacou Konan, Ph.D., who is working with FluroTech to develop the technology. Dr. Konans research program concentrates on virus detection and the mechanisms responsible for viral disease pathogenesis. The program is supported by a Biosafety Level 3 laboratory that allows for the use of highly virulent pathogens and is one of the few such facilities in the state of New York. Dr. Konan has obtained approval for COVID-19 work in his Biosafety Level-3 laboratory. As part of Albany Medical Center, the only academic medical center and Level 1 Trauma Center serving northeastern New York and western New England,Albany Medical College is in a unique position to begin large scale sample collection and clinical trials which will assist in obtaining regulatory/FDA approvals. My colleagues and I look forward to continuing our collaboration on antibodies with the science team of FluroTech led by Dr. Mauricio Arias and on fluorescence spectroscopy with Dr. Elmar Prenner from the University of Calgary, noted Dr. Konan. This initiative enriches our mission of patient care, research and educationthree critical factors to address this difficult viral problem for the people we serve.

FluroTech has a long-standing collaboration on fluorescence spectroscopy with Dr. Elmar Prenner. Dr. Prenner is the original developer of the core technology which is owned by Alberta BioPhotonics. Dr. Prenner, a professor at the University of Calgary within the department of Biological Sciences, serves as senior science advisor of FluroTech and brings over 28 years of expertise in fluorescence spectroscopy.

Elmar Prenner, Ph.D. and Senior Science Advisor of FluroTech, Mauricio Arias, Ph.D. and Kouacou Konan, Ph.D., have helped prepare and approve the proof of concept documentation that is summarized in this press release.

About Albany Medical Center

Albany Med, northeastern New Yorks only academic health sciences center, is one of the largest private employers in the Capital Region. It incorporates the 766-bed Albany Medical Center Hospital, which offers the widest range of medical and surgical services in the region, and Albany Medical College, which trains the next generation of doctors, scientists and other healthcare professionals. It also includes a biomedical research enterprise and the regions largest physicians practice with more than 500 doctors. Albany Med works with dozens of community partners to improve the regions health and quality of life. For more information: http://www.amc.edu.

About FluroTech (TSXV: TEST) (OTCQB: FLURF)

FluroTechs proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples for specific applications. Using technology that was first developed at the University of Calgary, FluroTech has created a two-part solution comprised of its CompleTest platform technology and consumable testing kits. Its accuracy has been independently validated. FluroTech continues to develop additional applications for the CompleTestplatform technology. To learn more, visit FluroTech.com

About FluroTest LLC

FluroTest is seeking additional capital in the near-term and will also be exploring strategic partnerships with manufacturing and distribution companies to advance the deployment of the new test thats being developed. To learn more, visit FluroTest.com

About Alberta BioPhotonics Inc.

Alberta BioPhotonics Inc. focuses on identifying market opportunities to commercialize its proprietary spectroscopy-based technology. ABP is controlled by some of the same officers and directors as FluroTech and currently holds approximately 33% of the common shares of FluroTech.

Contact Information

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuers business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuers prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the formation of FluroTest and the capital structure thereof, the ability to adapt FluroTechs CompleTestplatform technology to test for viruses, including COVID-19, as well as accurately determining viral load, the ability to adapt the technology to allow for the detection of specific anti-SARS-CoV-2 human antibodies in a patients blood sample, and the speed and accuracy of such testing, the need for financing of FluroTest in the near term and the formation of strategic partnerships for the deployment and distribution of the technology. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, as well as the ability to adopt the CompleTesttechnology as described herein in a timely manner and to obtain the financing required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporations Annual Information Form under the heading Risk Factors and the failure to adapt the CompleTesttechnology as contemplated herein in a timely manner or at all, the risk that competitors will develop a similar or superior testing platform, the technology not having the anticipated testing benefits, the inability of FluroTest to obtain the necessary financing to achieve its purpose on satisfactory terms or at all, the failure to form strategic partnerships necessary to deploy and distribute the technology. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

See the rest here:
Update to Previously Announced SARS-CoV-2 Test Development Initiative With Albany Medical College for the Presence of SARS-CoV-2 Virus - GlobeNewswire

Immunology

The lockdown may be over, but the pandemic is not – Varsity

September 8, 2020 medical

During the university lockdown caused by the pandemic, an initiative to promote the spread of pertinent information regarding COVID-19 was started by immunology students at UTSG. Graduate students in the Department of Immunology created educational pamphlets on important topics regarding COVID-19, including disease pathogenesis, current therapies, and the process of vaccine development.

As a current student in the Master of Science in Applied Immunology program, I was motivated to get involved and helped contribute to the creation of the vaccine development infosheet. The rationale behind this initiative was to generate scientifically accurate pamphlets that members of the general public can easily access in order to educate themselves and mitigate the spread of misleading information.

Remaining vigilant, maintaining hope

As of late July, Ontario had entered Stage 3, allowing businesses and services to reopen to promote the long-term restart and recovery of the economy. Although this provides a return to normalcy, it certainly does not mean the pandemic is over. Therefore, the information contained in the pamphlets continues to be valuable.

Despite the restrictions easing, this is a time to be more cautious, not more lenient. Currently, progress toward developing a safe and effective vaccine is still ongoing. It is imperative that the public remains vigilant in performing safety precautions to ensure their well-being and that of others.

It may be perceived that this gradual reopening signifies that the pandemic is no longer a threat of the same magnitude as it was earlier in the year, but COVID-19 is still very much a public health risk. This is reflected in the number of reported cases. According to Public Health Ontario there were more than 850 new cases in Ontario in the last week of August. Outbreaks are still occurring.

After the August long weekend, there was an outbreak at the Deerhurst Resort in Muskoka due to individuals reportedly not following physical distancing and social bubble guidelines. The Simcoe-Muskoka District Health Unit had entered Stage 3 a month earlier on July 17.

However, remaining cautious does not mean we should not be hopeful. Clinical trials are underway to generate a safe and efficacious vaccine, but it is important to acknowledge that this process takes time. Vaccine development occurs in several stages, including research of the virus, pre-clinical experimentation in animal models, and human clinical trial phases that test the safety and efficacy of the vaccine.

The pharmaceutical company AstraZeneca and Oxford University recently tested a vaccine candidate called ChAdOx1 nCoV-19, which has demonstrated safety in humans and an ability to generate neutralizing antibodies against SARS-CoV-2, which is the virus that causes COVID-19. ChAdOx1 nCoV-19 is undergoing phase three of clinical trials.

The information problem

During the 2016 outbreak of the Zika virus, a study found an increased usage of Twitter, Google search engine, Google News, YouTube, and Wikipedia pages to acquire Zika-related content. Although social media platforms and search engines allow for the spread of information in a timely manner, they can also be harmful due to the amount of false information being spread by unqualified users.

This is problematic as accurate information is often drowned out by misleading information. Additionally, certain users might see this information and be confused as to what is factual and what is not.

During the early stages of COVID-19, World Health Organization Director-General Tedros Adhanom Ghebreyesus referred to the spread of false and misleading COVID-19 information as an infodemic. He expressed that, like a virus, false information spreads rapidly and should be considered dangerous. Therefore, controlling the spread of misinformation on social media and online platforms is vital to ensure the public is receiving accurate knowledge.

It is understandably hard for platforms to manage information due to the number of social media users. Thus, the responsibility is put heavily on the internet user to ensure that they are accessing credible sources to acquire information. Accessibility to accurate information can be promoted by providing easy-to-read online documents and interesting graphics created by the government, academic institutions, and scientists.

Although vaccine development is underway, it is still important that we follow public health guidelines, stay informed via accurate sources, and take preventive measures to avoid a potential second wave of the virus.

Here is the original post:
The lockdown may be over, but the pandemic is not - Varsity

Immunology

Bruker Appoints Bonnie H. Anderson to its Board of Directors – Business Wire

September 8, 2020 medical

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that it has appointed Bonnie H. Anderson to serve on its board of directors, effective as of September 3, 2020.

Ms. Anderson is Co-Founder, Chairman of the Board and CEO of Veracyte, a global genomic diagnostics company that improves patient care by informing diagnosis and treatment decisions in cancer and other diseases. Before Veracyte, Ms. Anderson spent 18 years at Beckman Coulter, where she held leadership positions across the global life sciences and diagnostic business segments, including flow cytometry. After she retired from Beckman Coulter, Ms. Anderson was brought into a life sciences incubator formed by Kleiner Perkins, Versant Ventures and TPG Biotech, where she developed the concept for Veracyte. Veracyte is now a public global company with a market capitalization of nearly $2 billion.

"We are very pleased to welcome Bonnie to the Bruker board, and we especially value her entrepreneurial success, and her many years of genomics testing and diagnostics business expertise. She also has deep insights into oncology, hematology and immunology diagnostic tools and clinical workflows," said Frank Laukien, Brukers Chairman, President and CEO. "The addition of Bonnie to our board is very timely as we continue to evolve our Project Accelerate initiatives in multiomics life-science and clinical research tools towards molecular diagnostics solutions. Bonnie shares our goals to serve life science research and medicine with leading measurement tools and diagnostic solutions, and to enhance value for all of Brukers stakeholders."

I am honored to be appointed to the Bruker board, and I am looking forward to contributing to the success of such a dynamic and innovative company. I have admired the breakthrough work Bruker does in advancing life science and clinical research for many years, and I am thrilled to join such an impressive board, said Ms. Anderson.

Our board regularly evaluates its composition to ensure it includes the appropriate skills, experience and perspectives to support Brukers strategic direction. With Bonnies addition, seven new Bruker directors will have joined Brukers board in the past five years, including three women, said Marc Kastner, the Chair of Brukers Nominating & Governance Committee.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology and infectious disease molecular diagnostics. For more information, please visit: http://www.bruker.com.

Forward Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding managements expectations for future financial and operational performance, business strategy, business outlook and Board performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to continued adverse changes in conditions in the global economy and volatility in the capital markets, the impact of the COVID-19 coronavirus outbreak and our ability to recover from its effects, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates, our material weaknesses in internal controls, our ability to successfully implement our restructuring initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborative partners, key suppliers and contract manufacturers, capital spending and government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2019 and our subsequently filed Form 10-Qs. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Original post:
Bruker Appoints Bonnie H. Anderson to its Board of Directors - Business Wire

Immunology

IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and…

September 8, 2020 medical

POLLING, Germany, September 07, 2020 /B3C newswire/ --IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision canonical antibodies for the treatment of cancer, immune-system related diseases and Covid-19, today announced, that it has been successfully founded and funded.The company has secured three clinical candidates in IND-enabling stage and funding from MAB Discovery GmbH, originally generating the licensed antibodies from a novel antibody discovery platform. After 10 years of more than 50 successful monoclonal antibody discovery projects with large Pharma and mid- and large-size Biotech companies, MAB Discovery sold its antibody production platform and laboratory to BioNTech (NASDAQ: BNTX) in 2019. At the end of 2019, a pre-clinical project in the field of Immuno-oncology was licensed to a Top Pharma company.IcanoMAB will use the proceeds to advance the clinical candidates to allow IND-enabling activities and respective partnering activities with selected third parties.

Particularly urgent are effective treatments for Covid-19 and its potentially fatal outcome driven by Acute Respiratory Distress Syndrome (ARDS) and Cytokine Release Syndrome (CRS). While Vaccine development is progressing and sufficient broad population protection yet to be demonstrated, risks of detrimental effects via Antibody Dependent Enhancement (ADE) will require specific therapeutic intervention. In any case, an effective treatment is urgently needed as an option for clinicians to treat severely affected late-stage Covid-19 patients.Significant improvement of clinical outcome is also required for treatment of acute inflammatory conditions including several severe rare diseases like Macrophage-Activation Syndrome, SJIA / Stills Disease or IBD and Gout where sometimes even specific treatments are missing, addressing the underlying cause.The same holds true for clinical outcome in cancer therapy, whether it is the treatment of women with early Breast Cancer and especially through neo-adjuvant treatment, or via novel immuno-oncology treatments across multiple solid cancers.

While monoclonal antibody discovery has progressed significantly in the last decades, precise canonical antibodies have not been well exploited to address clinically validated and/or clinical targets in a physiological manner. The technology of MAB Discovery was developed to generate an unlimited number of diverse antibody-producing B-cells (>10,000) with optimal variability without additional in vitro maturation or engineering to optimize therapeutically relevant paratopes. Resulting antibodies have been applied to Pharma-derived high throughput screening in functional assays to identify lead candidates that fulfill a predefined list of biological activities and provide optimal potency essential for differential therapeutic application. Potential leads have gone through a sophisticated sequence optimization: Humanization, elimination of T-cell epitopes & potential CMC liabilities. Addressing validated targets generated proprietary molecules with novel modes of intervention and the knowledge of first-generation molecules enabled a well guided in vitro differentiation. This approach allows focused activities for in-vivo PoC in animal models and in the clinic with limited remaining CMC risks.

Addressing those needs, IcanoMAB's clinical lead candidates have been developed to date and are in collaborations with leading experts and renowned organizations across the world like

Link to the press release

Tweet this press release

AboutIcanoMABIcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system related diseases and Covid-19. The company is developing its proprietary clinical candidates to exploit novel approaches improving clinical outcome in immuno-oncology, solid tumors and immunology and inflammation.IcanoMAB was founded by highly experienced entrepreneurs and scientists with a track record of successful drug development in multiple companies including Boehringer Mannheim, Roche, MAB Discovery, Xantos Biomedicine, JSB Partners, Novartis and TVM Capital Life Science. The company was founded by MAB Discovery, represented by Dr. Stephan Fischer, CEO, Dr. Ulrich Pessara and Daniel Parera, M.D..IcanoMAB is headquartered in Polling, Germany.

About MAB DiscoveryFounded in 2010 by Dr. Stephan Fischer, MAB Discovery utilized a unique and proprietary rabbit-based antibody discovery platform to generate and develop high quality, functional monoclonal antibodies targeting traditional proteins and receptors as well as a wide variety of more challenging immunogens such as GPCRs and ion channels. Before the trade sale of its technology to BioNTech (NASDAQ: BNTX), MABD has used its proprietary platform to generate various mAbs for several pharma partners and for the generation of proprietary mAbs focusing on highly attractive targets with proven therapeutic relevance. In the meantime, MAB Discovery did focus on the development of its proprietary therapeutic monoclonal antibodies in inflammation and immuno-oncology.

Contact

IcanoMAB GmbHTassilostr. 2, 82398 Polling, Germany+49 881 39 90 89 40info@icanoMAB.com

Keywords: Animals; Humans; Binding Sites, Antibody; Antibodies, Monoclonal; Epitopes, T-Lymphocyte; Antibody Formation; Antibody-Producing Cells; Neoplasms; Models, Animal; Biotechnology; Cell Differentiation; B-Lymphocytes; Early Detection of Cancer; COVID-19

Published by B3C newswire

Originally posted here:
IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and...

Immunology

2020-2026 Update of Ulcerative Colitis Immunology Drugs Market Share, Growth Rate, Opportunities, Sales Channels and Porters Five Forces Analysis and…

September 8, 2020 medical

Ulcerative Colitis Immunology Drugs Market Report 2020 by Material, Application and Geographics Global Forecast to 2026 could be a skilled and comprehensive analysis report on the worlds major regional market conditions, specializing in the most regions (North America, Europe and Asia-Pacific) and therefore the main countries (United States, Germany, UK, Japan, South Korea and China). This analysis study examines the Ulcerative Colitis Immunology Drugs Market current trends associated with the demand, offer and sales, additionally to the recent developments. Major drivers, restraints, Associate in opportunities are lined to produce an thoroughgoing picture of the market. The analysis presents in-depth info relating to the event, trends and industry policies and rules being enforced by the relevant agencies. Further, the regulative framework of the Ulcerative Colitis Immunology Drugs market has been thoroughly lined to supply stakeholders a higher understanding of the key factors poignant the market environment.

Access Free Sample Copy of Ulcerative Colitis Immunology Drugs Market Report: https://calibreresearch.com/report/global-ulcerative-colitis-immunology-drugs-market-15856#request-sample

Identification of key industry players within the Ulcerative Colitis Immunology Drugs industry and their revenue contribution to the business or relevant section aligned to the study are lined as a vicinity of competitive intelligence done through in depth secondary analysis. Various studies and knowledge printed by industry associations, analyst reports, capitalist displays, press releases and journals among others are taken into thought whereas conducting the secondary analysis. Each bottom-up and prime down approaches are used to work out the Ulcerative Colitis Immunology Drugs market size of the market and key segments. The prices obtained are related to with the first inputs of the key stakeholders within the globe value chain. The last step involves complete market engineering which has analyzing the information from completely different sources and existing proprietary datasets whereas mistreatment various data triangulation strategies for market breakdown and statement.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

The Ulcerative Colitis Immunology Drugs market research concerned the study of Various factors poignant the industry, together with the govt. policy, market environment, competitive landscape, historical knowledge, present trends within the market, technological innovation, future technologies and therefore the technical progress in connected industry and risks, opportunities, barriers and challenges. The subsequent illustrative figure shows the marketing research methodology applied during this report.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert

Global Major Market Players indulged in this report are:

Janssen Biotech, Inc.Bristol-Myers Squibb CompanyAbbVie Inc.UCBCaresAMGENCelltrion HealthcareBiogenGenentech USA, Inc.ROCHEPfizer Inc.

The Ulcerative Colitis Immunology Drugs Market report is segmented into following categories:

The Ulcerative Colitis Immunology Drugs market report is segmented into Type by following categories;AdalimumabCertolizumab PegolTofacitinibEtanerceptGolimumabAbataceptInfliximabOthers

The Ulcerative Colitis Immunology Drugs market report is segmented into Application by following categories;Rheumatoid ArthritisCrohns Disease(CD)Ankylosing Spondylitis(AS)Psoriasis(Ps)Ulcerative Colitis(UC)

The report provides elaborate analysis on the Ulcerative Colitis Immunology Drugs market. This analysis provides forecasts for the provided amount in terms important (in US$) for the Ulcerative Colitis Immunology Drugs market, yet as for the revenue and cost markets. The report examines the economy of the country, hack import and provide, estimates the expenditure, capital acquisition and forecasts their growth for subsequent 5 years.

The Ulcerative Colitis Immunology Drugs Market report additionally analyzes factors that influence demand for the industry, key market trends and challenges round-faced by industry participants. It provides an in-depth analysis of different segments and drivers in the Ulcerative Colitis Immunology Drugs market together with highlights of the demand drivers and growth stimulators for the Ulcerative Colitis Immunology Drugs market. It additionally provides a exposure of the countrys economy and globe outlook. It provides details on the present trends for producing in globe together with policy initiatives, joint ventures, current necessities and locational attractiveness.

Checkout FREE Report Sample of Ulcerative Colitis Immunology Drugs Market Report for Better Understanding: https://calibreresearch.com/report/global-ulcerative-colitis-immunology-drugs-market-15856#request-sample

This Ulcerative Colitis Immunology Drugs Market report has been compiled by combining info obtained from a really wide and wealthy mixture of primary and secondary analysis sources, manufacturing a broad industry summary. These forecasts and analysis provided are underpinned by in depth knowledgeable consultation and embody interviews with industry consultants. The study attracts on a various vary of official company and governmental announcements, media reports, policy documents, industry statements and knowledgeable opinion as a basis for discussing and predicting developments within the Ulcerative Colitis Immunology Drugs market.

Visit link:
2020-2026 Update of Ulcerative Colitis Immunology Drugs Market Share, Growth Rate, Opportunities, Sales Channels and Porters Five Forces Analysis and...

Immunology

Allergies vs. COVID: KU doctors give tips on knowing the difference – Salina Post

September 7, 2020 medical

From left:: Dr. Dana Hawkinson, University of Kansas Health Center medical director of infection prevention and control; Dr. Steve Stites, chief medical officer; and Dr. Selina Gierer, specialist in allergy, immunology and rheumatology medicine. Image courtesy Hays Post

By CRISTINA JANNEYHays Post

Is that runny nose and cough COVID or just your run-of-the-mill seasonal allergies?

Doctors at the University of Kansas Health System tried to give viewers tips on how to distinguish between the two during their daily news briefing Wednesday.

Dr. Steve Stites, chief medical officer, and Dr.Dana Hawkinson, medical director of infection prevention and control, were joined byDr. Selina Gierer, specialist inallergy, immunology and rheumatology medicine, andear, nose and throat surgeon Dr. Keith Sale.

Gierer said Kansas has reached its peak allergy season. Children are also returning to school and can be exposed to viral infections.

"It is always a challenge when we go back to school when kids get any viral infection on top of season allergies trying to pick a part what's an illness and what is an allergy symptom," she said.

Itchy and water eyes as well as sneezing are common symptoms of allergies, but not of COVID-19.

Then there is an overlap zone for both allergies and COVID,Gierer said.

These include cough, fatigue, headache, sore throat, shortness of breath and runny nose.

"Ultimately, if you are having fever, if your symptoms are not typical for your allergy symptoms,"Gierer said, "perhaps this is not a typical allergy season for you.

"If you are having cough, if you are having congestion and you are having change in your sense of smell, it's time for you to be thinking about contacting your doctor to get tested for coronavirus."

She suggested keeping control of your allergy symptoms and avoiding people who are sick.

Monitor your triggers, such as dust, mold, pollen or animals. Monitor the local pollen count. Stay on your allergy medications.

"If you know you are going to be doing yard work, and the next day you feel itchy and drippy and sneezy, you can probably attribute that to your allergies and not an acute onset of coronavirus,"Gierer said.

Asthma is an underlying medical condition that increases the likelihood of complications from coronavirus. However, it is on the lower end of the range of complicating factors.

Asthma is much less common to cause complications than obesity and hypertension,Gierer said.

However, one of the biggest triggers of asthma is a viral infection. She said it is also important to keep your asthma under control by staying on medications, avoiding triggers and keeping a 30-day supply of medication on hand.

Sale saw a patient in his clinic who was having typical symptoms for allergies, such as a runny nose, but was not getting better on her normal medications.

She thought she had a sinus infection or something else. A friend from out of town had visited the week before. She was tested for COVID and was surprised with a positive COVID test, Sale said.

Sale said his office is taking COVID precautions, including using PPE, hand sanitizing between patients and patients wearing masks unless their nose or mouth is being examined.

Gierer said allergy medication or a rescue inhaler will probably not help with COVID-19 symptoms.

Sale said fatigue may be common to both allergies and COVID, but the persistence of the symptom may be a sign of the later.

Gierer said, "If the allergy medications are not working, that might trigger you to think there is something else going on."

Hawkinson said scientists are working to combine testing for flu and COVID-19. He said if a patient has a nasal swab for COVID-19, a lab could use that same sample to test for flu and RSV.

RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults, according the Centers for Disease Control.

The flu season is in full swing in South Africa and Australia and has been lighter this year there than in years past,Hawkinson said. He said that could be in part to mask use and increased hand washing.

KU Med is working on mass flu vaccination at this time.

Gierer urged members of the public to get flu vaccines. That is usually recommended starting in October.

The doctors also gave tips on staying in good general health.

You can naturally boost your immune system by getting adequate sleep, eating a healthy diet, as well as hand washing and staying away from people who are sick.

Those tips can help with COVID-19, flu or RSV.

Sale also said caring for your mental health can have an effect on maintaining physical health, which includes socializing in a safe way.

View post:
Allergies vs. COVID: KU doctors give tips on knowing the difference - Salina Post

Immunology

Immunology Drug Market To Witness An Impressive Growth During The Forecast Period 2017 2025 – The Daily Chronicle

September 7, 2020 medical

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Immunology Drug market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Immunology Drug market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Immunology Drug market to assist our clients arrive at beneficial business decisions.

The Immunology Drug market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Immunology Drug market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15259

What pointers are covered in the Immunology Drug market research study?

The Immunology Drug market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Immunology Drug market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Immunology Drug market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

key players and products offered

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15259

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Immunology Drug market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Immunology Drug market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Immunology Drug market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15259

Some of the Major Highlights of TOC covers:

Here is the original post:
Immunology Drug Market To Witness An Impressive Growth During The Forecast Period 2017 2025 - The Daily Chronicle

Immunology

AstraZeneca : New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented at the European Respiratory Society International Congress…

September 7, 2020 medical

* Breztri Aerosphere reduced rate of COPD exacerbations across all seasons compared with Bevespi Aerosphere

* AstraZeneca to present 60 abstracts from inhaled and biologics portfolio and pipeline at the ERS Congress

A post-hoc analysis of the Phase III ETHOS trial showed a consistent benefit of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations across all seasons compared with Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe disease.1

These data are among 60 AstraZeneca abstracts accepted for presentation, including 10 oral presentations, at the European Respiratory Society (ERS) International Virtual Congress 2020, between 7-9 September.

Gary Ferguson, Clinical Professor of Medicine at Michigan State University, Director of the Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, US and Investigator in the ETHOS trial, said: "Treating patients with chronic obstructive pulmonary disease can be challenging in the winter as they experience more frequent and more severe exacerbations, contributing to increased morbidity and mortality. Results from the ETHOS trial should give clinicians confidence that they can reduce moderate or severe exacerbations, even during winter when respiratory diseases can put additional strain on healthcare systems."

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "These additional data from the Phase IIIETHOS trial are important in supporting clinicians' understanding of the robust clinical profile of Breztri Aerosphere, which has been approved in the US, China and Japan and is under regulatory review in the EU. With 60 company abstracts accepted for presentation at ERS, there is a wealth of data across AstraZeneca's inhaled combinations and biologic medicines, which demonstrates our commitment to advancing clinical practice in respiratory disease."

AstraZeneca abstracts to be presented at the ERS International Congress 2020 include:

Breztri Aerosphere

Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial (Oral presentation: Abstract OA5238, Wednesday 09 September 16:50-17:50 CEST)

Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis (E-poster session: Abstract PA984, Monday 24 August)

Symbicort Turbuhaler (budesonide/formoterol)

LATE BREAKER: Reimbursement for asthma care is a universal barrier to achieving asthma symptom control: The SABINA III study (E-poster session: Abstract PA2665, Monday 24 August)

LATE BREAKER: Short-Acting ?2-Agonist Use in Asthma in Western Societies (E-poster session: Abstract PA2629, Monday 24 August)

Efficacy of as-needed budesonide/formoterol in mild asthma: pooled analysis of SYGMA 1 and 2 (E-poster session: Abstract PA2275, Monday 24 August)

Fasenra (benralizumab)

Real-world treatment patterns of benralizumab therapy for patients with severe asthma. (Oral presentation: Abstract OA4646, Tuesday 08 September 15:40-16:40 CEST)

LATE BREAKER: Benralizumab in severe asthma: preliminary results from the Italian ANANKE study (E-poster session: Abstract PA2609, Monday 24 August)

Tezepelumab

Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY (E-poster session: Abstract PA2269, Monday 24 August)

Early science

Profiling the impact of two JAK inhibitors (AZD0449 & AZD4604) in a pre-clinical model of allergic asthma (E-poster session: Abstract PA3302, Monday 24 August)

COPD

COPD is a progressive disease which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness.2 It affects an estimated 384 million people3 and is the third leading cause of death globally.4 Improving lung function, reducing exacerbations and managing daily symptoms such as breathlessness are important treatment goals in the management of COPD.2 A single COPD exacerbation can have a negative impact on lung function5, quality of life6 and increase the risk of hospitalisation.7 Additionally, even one COPD exacerbation that results in hospitalisation, increases the risk of death.8,9

Patients with COPD experience an increase in incidence of exacerbations and severe exacerbations during the winter.10,11 Studies have also shown higher rates of COPD hospital admissions and more respiratory-related deaths in winter compared with summer months.10-13

ETHOS

ETHOS is a randomised, double-blind, multi-centre, parallel-group, 52-week trial to assess the efficacy and safety of Breztri Aerosphere in symptomatic patients with moderate to very severe COPD and a history of exacerbation(s) in the previous year. The primary endpoint was the rate of moderate or severe exacerbations. Results were published in the New England Journal of Medicine.14

Breztri Aerosphere

Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) is a single-inhaler, fixed dose triple-combination of budesonide, an inhaled corticosteroid (ICS), with glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-agonist (LABA), delivered in a pressurised metered-dose inhaler.

AstraZeneca in Respiratory & Immunology

Respiratory & Immunology is one of AstraZeneca's three therapy areas and is a key growth driver for the Company.

Building on a 50-year heritage, AstraZeneca is an established leader in respiratory care, across inhaled and biologic medicines. AstraZeneca aims to transform the treatment of asthma and COPD by eliminating preventable asthma attacks across all severities and removing COPD as a leading cause of death through earlier biology-led treatment. The Company's early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell-repair processes in disease and neuronal dysfunction.

With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas. The Company's growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential in rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. AstraZeneca's ambition in immunology is to achieve disease control and ultimately clinical remission in targeted immune-driven diseases.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

References

1. Ferguson GT, Rabe KF, Martinez FJ, et al. Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial. Abstract OA5238 [Oral Presentation]. Presented at the European Respiratory Society International Virtual Congress 2020 (7th-9th September).

2. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. [Online]. Available at: http://goldcopd.org. [Last accessed: September 2020].

3. Adeloye D, Chua S, Lee C, et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020415.

4. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018; 3: e4. Published 2018 Apr 6. doi:10.1017/gheg.2018.1.

5. Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respiratory Medicine 2017; 128: 85-91.

6. Roche N, Wedzicha JA, Patalano F, et al. COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study. Eur Resp J. 2017; 50 (Suppl 61): OA1487.

7. Rothnie KJ, Mllerov H, Smeeth L, Quint JK. Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. Am Jour of Resp Crit Care Med. 2018; 198 (4): 464-471.

8. Ho TW, Tsai YJ, Ruan SY, et al. In-Hospital and One-Year Mortality and Their Predictors in Patients Hospitalized for First-Ever Chronic Obstructive Pulmonary Disease Exacerbations: A Nationwide Population-Based Study. PLOS ONE. 2014; 9 (12): e114866.

9. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957-63.

10. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012; 39: 38-45.

11. Wise RA, Calverley PMA, Carter K et al. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR trial. Int J Chron Obstruct Pulmon Dis. 2018;13:605-616.

12. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2014; 9: 1101-1110.

13. Chakraborti A, Ramanathan R. Alunilkummannil J. Seasonal variations in outcomes and costs for COPD. Chest 2019; 156 (4) Suppl: A1164.

14. Rabe KF, Martinez FJ, Ferguson GT, et al. Inhaled Triple Therapy at Two Glucocorticoid Doses in Moderate-to-Very Severe COPD. N Engl J Med 2020; 383:35-48.

See the rest here:
AstraZeneca : New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented at the European Respiratory Society International Congress...

Immunology

Hill Named COO of Southern Administrative (Movers & Shakers) – Arkansas Business Online

September 7, 2020 medical

We were unable to send the article.

Tim Hill of Southern Administrative Services Tim Hill became the chief operating officer of Southern Administrative Services on Aug. 1. SAS uses the Green House Cottage model of nursing home care. In Hills new role he will be responsible for all aspects of elder care operations, quality and safety programs, census development and talent management.

We will look for every opportunity to create a system where we share best practices among client facilities and leverage our position in the market, Hill said in a press release.

Hill has more than 27 years of health care finance and operational management experience. He had served as COO of the University of Arkansas for Medical Sciences Health System since 2017, after fulfilling several roles there since 2011. Over the years, he has had several senior positions for a number of health care organizations, including CEO of Arkansas Heart Hospital in Little Rock and North Arkansas Regional Medical Center in Harrison. The Arkansas Hospital Association named him Administrator of the Year in 1996, when he was running Southwest Hospital in Little Rock.

Hill earned a bachelors degree in business, finance and accounting from St. Cloud State University in Minnesota.

Dr. Erica Horta of UAMS in Little Rock Dr. Erica Horta has been hired as a neuro-immunologist at the University of Arkansas for Medical Sciences in Little Rock.

Horta specializes in multiple sclerosis and brain and spine tumors. She also serves as an assistant professor in the department of neurology in the UAMS College of Medicine.

Horta earned her medical degree and completed a residency and a clinical fellowship at the University of Sao Paulo in Brazil. Horta also completed a fellowship in research at the Neuro-immunology Laboratory at the Mayo Clinic in Rochester, Minnesota, and a clinical fellowship in neuro-oncology at Henry Ford Hospital in Detroit. She also served a residency in neurology at the University of Minnesota in Minneapolis.

Dr. Kim Jackson of Little Rock Allergy & Asthma Clinic. Dr. Kim Jackson has been hired as a physician at the Little Rock Allergy & Asthma Clinic.

Jackson earned her medical degree at the American University of the Carribean and completed residency for internal medicine at Louisiana State University in Shreveport. She has been published within the fields of allergy, immunology, and internal medicine, and has made oral presentations at local and national professional conferences.

Nicholas B. Wilson of Martin Orthopedics in Little Rock. Nicholas B. Wilson has been hired as a new surgeon at Martin Orthopedics in Little Rock. Wilson earned his medical degree from St. Louis University School of Medicine and completed an orthopedic residency at Mount Carmel Health System in Columbus, Ohio. Wilson has also led a number of research programs including a biomechanics program at Nationwide Childrens Hospital in Columbus and a therapy program for the Cardinals Reminiscence League at St. Louis University.

Dr. Matt Peckat has joined Baptist Health Family Clinic in Bryant.

Peckat received his medical degree from the University of Arkansas for Medical Sciences and completed his residency training through the UAMS Southwest Family Medicine Residency Program in Texarkana.

See more of this week's Movers & Shakers, and submit your own announcement at ArkansasBusiness.com/Movers.

Immunology

Allergies vs. COVID: KU doctors give tips on knowing the difference – hays Post

September 6, 2020 medical

LEFT to RIGHT: Dr. Dana Hawkinson, University of Kansas Health Center medical director of infection prevention and control; Dr. Steve Stites, chief medical officer; andDr. Selina Gierer, specialist in allergy, immunology and rheumatology medicine.